To determine whether the composition of the faecal microbiome in CRC patients differs according to clinicopathological and tumour molecular features, beta diversity using Bray–Curtis distances was calculated based on tumour stage, tumour location, MSI status, and KRAS and BRAF mutation status (Fig. 4). The gene discussed is BRAF; the disease is neoplasm.